基石藥業-B(02616.HK)：泰吉華®就中國GIST晚期患者更新研究結果亮相2021年ESMO世界胃腸道腫瘤大會
格隆匯7月8日丨基石藥業-B(02616.HK)發佈公吿，基石藥業在歐洲消化腫瘤協會胃腸道腫瘤(“ESMO GI”)2021線上年會上以口頭短報吿形式公佈了泰吉華®(阿伐替尼片)就中國胃腸道(“胃腸道”)間質瘤(“GIST”)晚期患者的I/II期臨牀研究數據。此次研究結果的發佈，將為GIST患者的治療帶來新的研究證據，並有助改善臨牀實踐。
根據披露，泰吉華®是一款強效、高選擇性、口服針對KIT和PDGFRA突變的抑制劑，由基石藥業合作伙伴Blueprint Medicines(NASDAQ: BPMC)開發。基石藥業與Blueprint Medicines達成獨家合作和授權協議，在中國大陸、中國香港、中國澳門和中國台灣開發和商業化包括泰吉華®在內的多款藥物。Blueprint Medicines將保留泰吉華®全球其它地區的開發和商業化權利。本次關鍵亮點包括泰吉華®對攜帶PDGFRA D842V突變的中國GIST患者展示出優越和持久的抗腫瘤活性，對四線及以上的GIST患者也展示出治療潛力；及泰吉華®在中國GIST患者人羣中安全性和耐受性良好，與全球其他研究結果一致。
泰吉華®中國研究的主要研究者、北京大學腫瘤醫院副院長沈琳教授表示：“由於現有療法的獲益極為有限，PDGFRAD842V突變的GIST患者具有高度未滿足的治療需求。這次ESMO GI更新的數據，進一步驗證了泰吉華®在PDGFRA外顯子18突變的中國晚期GIST患者中表現出了非常好的抗腫瘤活性，對四線及以上既往治療的GIST患者展示了治療的潛力，且安全性和耐受性良好，期待泰吉華®為患者帶來重要的額外治療選擇。”
基石藥業首席醫學官楊建新博士表示：“我們很高興看到泰吉華®在這次ESMO GI會議上公佈中國GIST患者中的I/II期橋接研究的更新數據。研究顯示泰吉華®在中國患者中耐受性良好，進一步驗證出該藥對攜帶PDGFRA外顯子18突變(包括PDGFRAD842V突變)的中國患者具有突出的抗腫瘤活性，同時對四線及以上的中國GIST患者展示了良好的治療潛力，我們期待泰吉華®惠及更多GIST患者。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
